Rationale for combination therapy of chronic myelogenous leukaemia with imatinib and irradiation or alkylating agents: Implications for pretransplant conditioning

British Journal of Cancer

Volumn 86, Issue 9, 2002, Pages 1487-1493

  Topaly, J ^a   Fruehauf, S ^a   Ho, A D ^a   Zeller, W J ^a  

^a GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

Author keywords

Chronic myelogenous leukaemia; Gleevec; Glivec; Imatinib; Irradiation; STI571

Indexed keywords

ALKYLATING AGENT; BCR ABL PROTEIN; BUSULFAN; IMATINIB; TETRAZOLIUM; TREOSULFAN;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CALCULATION; CANCER COMBINATION CHEMOTHERAPY; CANCER INHIBITION; CANCER RADIOTHERAPY; CHRONIC MYELOID LEUKEMIA; CONTROLLED STUDY; DRUG ANTAGONISM; DRUG EFFECT; DRUG POTENTIATION; GAMMA IRRADIATION; HUMAN; HUMAN CELL; IN VITRO STUDY; PRIORITY JOURNAL; STEM CELL TRANSPLANTATION; TUMOR CELL LINE; TUMOR GROWTH;

ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC AGENTS, ALKYLATING; BUSULFAN; CELL DIVISION; COMBINED MODALITY THERAPY; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LEUKEMIA, MYELOID, CHRONIC; PIPERAZINES; PYRIMIDINES; RADIOTHERAPY; TUMOR CELLS, CULTURED;

EID: 0037029687     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjc.6600242     Document Type: Article

References (36)

1. Autografting with Philadelphia chromosome-negative mobilized hematopoietic progenitor cells in chronic myelogenous leukaemia
2. Toxicity-reduced conditioning with treosulfan and fludarabine prior to allogeneic blood stem cell transplantation
3. Quantitative analysis of dose-effect relationships: The combined effects of multiple drugs or enzyme inhibitors
4. Marrow transplantation for chronic myeloid leukaemia: A randomized study comparing cyclophosphamide and total body irradiation with busulfan and cyclophosphamide
5. BCR-ABL tyrosine kinase activity regulates the expression of multiple genes implicated in the pathogenesis of chronic myeloid leukaemia
6. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of bcr/abl positive cells
7. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome
8. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukaemia
9. A phase I study of gleevec (Imatinib Mesylate) administered concomitantly with cytosine arabinoside (Ara-C) in patients with Philadelphia positive chronic myeloid leukemia (CML)
10. The biology of chronic myeloid leukaemia
11. Comparison of in vitro activity of cytotoxic drugs towards human carcinoma and leukaemia cell lines
12. Intensification of induction and consolidation improves only subgroups of adult ALL: Analysis of 1200 patients in GMALL study 05/93
13. Hematopoietic cell transplantation in acute lymphoblastic leukaemia: Better long term event-free survival with conditioning regimens containing total body irradiation
14. Risk assessment for patients with chronic myeloid leukaemia before allogeneic blood or marrow transplantation
15. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification
16. Roots of clinical resistance to STI-571 cancer therapy
17. Oral busulfan pharmacokinetics and engraftment in children with Hurler syndrome and other inherited metabolic storage diseases undergoing hematopoietic cell transplantation
18. In vitro cytotoxic effects of a tyrosine kinase inhibitor STI571 in combination with commonly used antileukemic agents
19. Clinical course and therapy of chronic myelogenous leukaemia with interferon-alpha and chemotherapy
20. Favorable therapeutic index of a p210(BCR-ABL)-specific tyrosine kinase inhibitor; activity on lineage-committed and primitive chronic myelogenous leukaemia progenitors
21. Autologous transplantation of blood-derived hemopoietic stem cells after myeloablative therapy in a patient with Burkitt's lymphoma
22. An alteration of the human c-abl protein in K562 leukaemia cells unmasks associated tyrosine kinase activity
23. Dihydroxybusulfan (NSC-39069) in chronic myelocytic leukaemia and miscellaneous malignant neoplasms
24. Rapid colorimetric assay for cellular growth and survival: Application to proliferation and cytotoxicity assay
25. Relation of blast cell survival and proliferation to chemotherapy resistance in AML
26. A minute chromosome in chronic granulocytic leukaemia
27. Adaptation of the rapid automated tetrazolium dye based (MTT) assay for chemosensitivity testing in childhood leukaemia
28. Autologous stem cell transplantation in chronic myeloid leukaemia: A single center experience
29. Treosulfan as an alternative conditioning agent in bone marrow transplantation
30. A new consistant chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining
31. Clinical phase I dose escalation and pharmacokinetic study of high-dose chemotherapy with treosulfan and autologous peripheral blood stem cell transplantation in patients with advanced malignancies
32. A phase II study of STI571 in adult patients with Philadelphia chromosome positive chronic myeloid leukaemia in accelerated phase
33. Efficacy of STI571 an abl tyrosine kinase inhibitor, in conjunction with other antileukemic agents against BCR-ABL-positive cells
34. Synergistic activity of the new ABL-specific tyrosine kinase inhibitor STI571 and chemotherapeutic drugs on BCR-ABL-positive chronic myelogenous leukaemia cells
35. Prognostic value of minimal residual disease in acute lymphoblastic leukaemia in childhood